Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses.

Frontiers in immunology·2026

Same author

A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules.

Cancer research·2025

Same author

DeRR: A Unique Detecting Method and the First Landscape for T Cells with Dual T Cell Receptors from Large-scale Single Cell Data.

Genomics, proteomics & bioinformatics·2025

Same author

Insights into ROL-driven and ROS-mediated metalloid oxidation and sequestration in the soil-rice iron barrier system.

Journal of hazardous materials·2025

Same author

Protein Immobilization Inspired Lysosomal Disruption for Efficient Nuclear Drug Delivery.

ACS applied materials & interfaces·2025

Search research articles

Related Experiment Video

Updated: Jun 29, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

A Predictive Network-Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and

Nan Zhang¹, Mei Yang¹, Jing-Min Yang¹

¹Hubei Bioinformatics & Molecular Imaging Key Laboratory, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China.

|March 28, 2024

Summary

A new computational tool, ICBnetIS, accurately predicts patient responses to immune checkpoint blockade (ICB) therapy. This network-based signature improves patient selection for cancer treatment, outperforming existing methods.

Keywords:

ICB therapy response prediction anti‐tumor immune pathways biological network‐based computational strategies immune checkpoint blockade (ICB) therapy immunotherapeutic signature (IS)

More Related Videos

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jun 29, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Oncology
Immunotherapy
Computational Biology

Background:

Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment.
Patient responses to ICB vary significantly, necessitating improved predictive biomarkers.
Understanding tumor-immunology pathways is crucial for optimizing ICB efficacy.

Purpose of the Study:

To develop a novel network-based immunotherapeutic signature for predicting ICB response.
To validate the predictive capability of the signature across diverse cancer types.
To enhance patient stratification for personalized oncology treatment.

Main Methods:

Construction of a novel signature, ICBnetIS, using biological network-based computational strategies.
Analysis of co-expression and molecular interaction networks.
Validation using ICB data from over 700 samples across multiple cancer types and datasets.

Main Results:

ICBnetIS is associated with enhanced patient survival and robust anti-tumor immune responses.
The signature achieved a high aggregated prediction AUC of 0.784.
ICBnetIS outperformed nine other established immunotherapeutic signatures in predictive accuracy.

Conclusions:

ICBnetIS is a potent and superior tool for predicting response to ICB therapy.
The signature has significant implications for patient selection and treatment optimization in oncology.
ICBnetIS advances personalized medicine strategies in cancer care.